1 (4) 0 ATL, adult T-cell leukemia/lymphoma; AZT, zidovudine; CCR4, C-C chemokine receptor 4; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; CVAD, cyclophosphamide, vincristine, cyclophosphamide, and doxorubicin; ECOG, Eastern Cooperative Oncology Group; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; ICE, ifosfamide, carboplatin, and etoposide; PD, progressive disease; PR, partial response; SCT, stem cell transplantation; SD, stable disease. *Not reported for those countries that do not allow race/ethnicity data to be collected.
†This patient met eligibility criteria with disease in blood and not in lymph nodes according to the investigator but showed lymph node and no blood involvement on independent review. SD  13  NI  NI  SD  NI  NI  NI  14  CR  SD  SD  NI  SD  NR  15  CR  NI  SD  NI  NI  SD  16  CR  NI  PR  NI  NI  NI  17  CR  NI  PR  NI  NI  NI  18  CR  NI  SD  NI  NI  NR  19  CR  CR  ND  ND  ND  NI  20  SD  SD  SD  NI  NI  SD  21  CR  CR  SD  NI  NI  NI  22  CR  NI  SD  NI  NI  NI  23  CR  NI  PR  NI  NI  NR  24 NI PR PD SD NI NI CR, complete response; ND, not done; NI, no disease involvement; NR, not reassessed after baseline; PD, progresssive disease; PR, partial response; SD, stable disease; uCR, uncertified complete response.
*Biopsy showed reactive node. NOTE: Data are given as n (%) unless otherwise stated. CR, complete response; CRu, uncertified CR; ITT, intent-to-treat; PD, progressive disease; PR, partial response; SD, stable disease. †All but one patient considered not evaluable for overall response received ≤1 cycle of treatment and did not have assessments for response . Of these, on the mogamulizumab arm, reasons for treament discontinuation from mogamulizumab were; adverse event (7), PD (6), death (2), withdrawal of consent (1), other (1); On the IC arm, PD (4), adverse event (2) withdrawal of consent (1)}. All were counted as non-responders for ORR in the ITT analysis. The patient on the IC arm who completed >1 treatment cycle, met eligibility criteria with disease in blood on local flow and not in lymph nodes according to the investigator but showed lymph node and no blood involvement on independent review and so was considered not evaluable for response by investigator assessment. One subject in crossover received 7 infusions of mogamulizumab and was discontinued from treatment due to an adverse event. Although this patient had a CR in blood and CR in skin, CT scan was not performed and so was not evaluable for overall response (See patient 19 in Figure 4 ). *If there was no post-baseline tumor assessment for response assessment or there was no disease in that compartment, the response was designated not assessable.
